Abstract:Abstract Background Multiple sclerosis (MS) and neuromyelitis optica syndrome disease (NMOSD) are inflammatory diseases of the central nervous system. The pathogenesis and treatments for these two conditions are very different. Natural killer (NK) and natural killer T (NKT) cells are immune cells with an important role in shaping the immune response. B cells are involved in antigen presentation as well as antibody and cytokine production. There is conflicting evidence of the roles of NK, NKT, and B cells in the two conditions. We aimed to compare the frequency of CD3 − CD16 + CD56 + NK, CD3 + CD56 + NKT, and CD5 + CD19 + B cells in the peripheral blood and serum Interleukin-10 (IL-10) in patients with MS and NMOSD. Methods CD19 + CD5 + B, CD3 − CD16 + CD56 + NK, and CD3 + CD56 + NKT cells were quantitated by flow cytometry in 15 individuals with Interferon-Beta (IFN-β) treated relapsing–remitting MS (RRMS), 15 untreated RRMS, and 15 NMOSD patients as well as 30 healthy controls (HC). Serum IL-10 was measured using an enzyme-linked immunosorbent assay (ELISA). Results The percentage of CD3 − CD56 + CD16 + NK cells in the peripheral blood of IFN-treated MS (1.81 ± 0.87) was significantly lower than for untreated RRMS (4.74 ± 1.80), NMOSD (4.64 ± 1.26) and HC (5.83 ± 2.19) (p < 0.0001). There were also differences for the percentage of CD3 − CD16 + and CD3 − CD56 + cells (p < 0.001 and p < 0.0007; respectively). IFN-treated RRMS (2.89 ± 1.51) had the lowest proportion of CD3 + CD56 + among the study groups (p < 0.002). Untreated RRMS (5.56 ± 3.04) and NMOSD (5.47 ± 1.24) had higher levels of CD3 + CD56 + than the HC (3.16 ± 1.98). The mean percentage of CD19 + CD5 + B cells in the peripheral blood of untreated RRMS patients (1.32 ± 0.67) was higher compared to the patients with NMOSD (0.30 ± 0.20), HC (0.5 ± 0.22) and IFN-treated RRMS (0.81 ± 0.17) (p < 0.0001). Serum interleukin-10 was significantly higher in the IFN-treated RRMS (8.06 ± 5.39) and in HC (8.38 ± 2.84) compared to untreated RRMS (5.07 ± 1.44) and the patients with NMOSD (5.33 ± 2.56) (p < 0.003). Conclusions The lower proportion of CD3 − CD56 + CD16 + NK and CD3 + CD56 + cells in peripheral blood of IFN-treated RRMS compared to other groups suggests the importance of immunomodulation in patients with RRMS disorder. Based on the differences in CD19 + CD5 + B cells and serum IL-10 between patients and HC, supplementary assessments could be of value in clarifying their roles in autoimmunity.

The detection and clinical significance of CD4~+CD25~+ regulatory T cell in peripheral blood of patients with multiple sclerosis and neuromyelitis optica

Detection of Foxp3+ CD4+ CD25+ Regulatory T Cells in the Peripheral Blood of Patients with Condyloma Acuminatum and Its Significance

[Clinical Significance of CD4+CD25+ T Cells in Peripheral Blood of Patients in Systemic Lupus Erythematosus].

Expression and Significance of Intracellular IL-13 and IL-5 in Peripheral Blood CD4~+ and CD8~+ T Cells from Patients with Multiple Sclerosis

Decreased 4-1Bb Expression on Cd4+Cd25(High) Regulatory T Cells in Peripheral Blood of Patients with Multiple Sclerosis

The frequencies of peripheral blood CD5+CD19+ B cells, CD3−CD16+CD56+ NK, and CD3+CD56+ NKT cells and serum interleukin-10 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder

Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis

Study of the Expression of CD_4~+CD_(25)~+T Cell and Soluble Cytokines of Peripheral Blood in the Cases of Multiple Sclerosis

Study on memory T cell subsets in peripheral blood of patients with multiple sclerosis

Change of CD4~+CD25~+-T Regulatory Cells in the Peripheral Blood of Patients with nervous autoimmune diseases and its signification

The Study on Secretion of Cytokine Interleukin-4, Interleukin-10 and Interferon-Γ in Peripheral Blood of Multiple Sclerosis Patients

Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy

Expression and significance of CD4+CD25high regulatory T cells in patients with non-small-cell lung cancer

Correlation between abnormal expression of CD4+CD25+CD127low/-regulatory T cells and multiple myeloma

Correlation between peripheral blood CD4+CD25high CD127low regulatory T cell and clinical characteristics of patients with non-Hodgkin's lymphoma

Characterization of antigen-specific CD8+ memory T cell subsets in peripheral blood of patients with multiple sclerosis

Ex Vivo Expansion of Antigen-Specific CD4+CD25+ Regulatory T Cells from Autologous Naïve CD4+ T Cells of Multiple Sclerosis Patients As a Potential Therapeutic Approach.

Circulating CD45RA-Foxp3++ Treg cells serve as a biomarker for predicting minimal clinical manifestations status of myasthenia gravis

Detection and Clinical Significance of Treg and Th1,Th2 Cells in Peripheral Blood of Patients with Immune Thrombocytopenia

Expression of CD+4CD+25 regulatory T cell in peripheral blood of HIV/AIDS patients with different TCM syndromes

The Differential Expression of Natural Killer Cells in NMOSD and MS